Here's how JTD.AMEGROUPS.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

JTD . AMEGROUPS . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Jtd.amegroups.org Make Money
  6. Keywords
  7. Topics
  8. External Links
  9. Analytics And Tracking
  10. Libraries
  11. CDN Services

We are analyzing https://jtd.amegroups.org/article/view/50178/html/page/about/quality-control-system.

Title:
Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma - Shen - Journal of Thoracic Disease
Description:
Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
Website Age:
6 years and 6 months (reg. 2018-12-14).

Matching Content Categories {📚}

  • Health & Fitness
  • Science
  • Insurance

Content Management System {📝}

What CMS is jtd.amegroups.org built with?

Custom-built

No common CMS systems were detected on Jtd.amegroups.org, but we identified it was custom coded using Bootstrap (CSS).

Traffic Estimate {📈}

What is the average monthly size of jtd.amegroups.org audience?

🚀 Good Traffic: 50k - 100k visitors per month


Based on our best estimate, this website will receive around 50,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Jtd.amegroups.org Make Money? {💸}

We don’t know how the website earns money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Jtd.amegroups.org might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

patients, cancer, neoadjuvant, lung, surgery, study, treatment, chemotherapy, crossref, pubmed, pembrolizumab, stage, therapy, resectable, response, journal, pathological, cell, medicine, nsclc, oncol, annals, resection, cases, survival, immunotherapy, disease, tumor, rate, trial, nonsmallcell, lusc, pcr, postoperative, evaluation, followup, aes, advanced, hospital, research, regimen, surgical, complete, criteria, efficacy, chemoimmunotherapy, pdl, cycles, complications, tumors,

Topics {✒️}

strobe reporting checklist facebook share case report form video-assisted thoracoscopy small-cell lung cancer precision medicine journal small-cell lung cancers translational medicine art drugs targeting t-cell iib–iiib lusc open access statement egfr-mutant lung cancer gastrointestinal oncology journal consolidation immuno-oncology therapy reverse kaplan-meier method determine progression-free survival maxillofacial anesthesia journal anti-pd-1 therapy based resectable lung cancer pd-l1 sequential treatment stage iiia–n2 disease acceptable side-effect profile recurrence-free survival—defined stage iiib cases programmed cell death lung adenocarcinoma cancer previous medical treatment palliative medicine annals breast surgery annals lung cancer surgery indicating pathological assessment lung cancer-reply severe intraoperative complications updated clinical research iiib lusc evaluated ethical statement health policy journal major pathological response surgery australian journal spine surgery journal visualized surgery journal neoadjuvant therapy-related aes pd-l1 level pd-l1-positive kaplan–meier method programmed death-ligand 1 nasopharynx cancer annals pancreatic cancer annals resected lung cancer surgical resection prior

External Links {🔗}(126)

Analytics and Tracking {📊}

  • Google Analytics
  • Google Analytics 4
  • Google Tag Manager

Libraries {📚}

  • AOS
  • Bootstrap
  • jQuery
  • Modernizr
  • Video.js
  • Zoom.js

CDN Services {📦}

  • Amegroups
  • Crossref

8.4s.